Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer.

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-09-15 eCollection Date: 2023-01-01 DOI:10.1080/2162402X.2023.2257098

Marion Thibaudin, Francois Ghiringhelli

引用次数: 0

Abstract

Checkpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients. Microsatellite-stable tumors are thought to be immunoresistant. A recent publication demonstrates that, contrary to the standard view point, the combination of chemo-immunotherapy could trigger a tumor-specific immune response, leading to clinical benefit.

Abstract Image

查看原文本刊更多论文

化学免疫疗法触发针对微卫星稳定的癌症结直肠癌的免疫应答。

检查点阻断免疫疗法改变了许多类型的癌症；然而，在转移性癌症领域，检查点阻断剂仅对微卫星稳定肿瘤有效，这些肿瘤仅代表少数患者。微卫星稳定肿瘤被认为具有免疫抗性。最近的一份出版物表明，与标准观点相反，化学免疫疗法的组合可以引发肿瘤特异性免疫反应，从而带来临床益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.